Glioblastoma News and Research RSS Feed - Glioblastoma News and Research

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Patterns of DNA anomalies can predict outcomes in women with ovarian cancer

Patterns of DNA anomalies can predict outcomes in women with ovarian cancer

Nearly anyone touched by ovarian cancer will tell you: it's devastating. It's bad enough that cancer in almost 80 percent of patients reaches advanced stages before diagnosis, and that most patients are expected to die within five years. But just as painfully, roughly one quarter of women diagnosed have no warning that they are resistant to platinum-based chemotherapy, the main line of defense, nor that they will likely have 18 months to live. [More]
Neuro-oncology researchers identify mechanism responsible for tumor cell invasion in glioblastoma

Neuro-oncology researchers identify mechanism responsible for tumor cell invasion in glioblastoma

A neuro-oncology research team at Dartmouth's Norris Cotton Cancer Center, led by the Director Mark A. Israel, MD with first author Gilbert J. Rahme, PhD, recently identified the transcription factor Id4 as a suppressor of tumor cell invasion in glioblastoma. [More]
Biologists discover vulnerability of brain cancer cells

Biologists discover vulnerability of brain cancer cells

Biologists at MIT and the Whitehead Institute for Biomedical Research have discovered a vulnerability of brain cancer cells that could be exploited to develop more-effective drugs against brain tumors. [More]
Study suggests possibility of developing personalized treatments for brain cancer

Study suggests possibility of developing personalized treatments for brain cancer

DNA mutations can cause cancer but in some cases, more mutations may mean a better prognosis for patients. A Yale-led comprehensive genomic analysis of more than 700 brain tumors has revealed one such subtype of the most malignant brain tumor, called glioblastoma, or GBM. This subtype possesses thousands of tumor-specific DNA errors or mutations instead of dozens observed in most glioblastoma cases. It is also associated with longer survival. [More]
Scientists identify small RNA molecule that can suppress cancer-causing genes in GBM

Scientists identify small RNA molecule that can suppress cancer-causing genes in GBM

Northwestern Medicine scientists have identified a small RNA molecule called miR-182 that can suppress cancer-causing genes in mice with glioblastoma mulitforme (GBM), a deadly and incurable type of brain tumor. [More]
Novogen appoints PCG Advisory to manage investor-awareness program in the US

Novogen appoints PCG Advisory to manage investor-awareness program in the US

Novogen Ltd today announced it has appointed US-based public relations firm, PCG Advisory (PCG), to drive the Company's investor-awareness program in the US. PCG will be using their expertise in creating awareness and establishing key relationships within the US investment community via their targeted outreach campaign. [More]
BeyondSpring files two patent applications to expand therapeutic scope of Plinabulin

BeyondSpring files two patent applications to expand therapeutic scope of Plinabulin

BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed two new method of treatment patent applications with the United States Patent and Trademark Office to cover methods of treating brain tumors as well as cancers expressing a mutant form of RAS protein through administration of the Company’s lead compound, Plinabulin. [More]
Personalized gene therapy to fight against cancer

Personalized gene therapy to fight against cancer

The fight to treat cancer and eradicate tumors will likely benefit from a new set of treatments if early development phases continue to show promise, according to Kalorama Information. The healthcare market research publisher stated that gene therapies that are able to deliver genetic material to a specific cell population or tumor that will result in the destruction of the tumor. [More]
2015 Minds Matter event raises funds to support brain tumor research

2015 Minds Matter event raises funds to support brain tumor research

One day in 2009, Maria Nijim's father got behind the wheel of his car and realized he couldn't see out of one eye. An MRI showed a tumor and then surgery confirmed a devastating diagnosis – glioblastoma – the most aggressive type of brain tumor. [More]
Researchers find way to enhance effects of immunotherapy in glioblastoma

Researchers find way to enhance effects of immunotherapy in glioblastoma

When cancer strikes, it may be possible for patients to fight back with their own defenses, using a strategy known as immunotherapy. According to a new study published in Nature, researchers have found a way to enhance the effects of this therapeutic approach in glioblastoma, a deadly type of brain cancer, and possibly improve patient outcomes. [More]
ImmunoCellular, PharmaCell sign manufacturing agreement for European production of ICT-107

ImmunoCellular, PharmaCell sign manufacturing agreement for European production of ICT-107

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with PharmaCell B.V. to provide contract manufacturing services for the European production of ICT-107, a dendritic cell-based cancer immunotherapy in development as a potential treatment for glioblastoma (GBM). [More]
New radiation treatment for brain cancer implanted in first human being at CTRC

New radiation treatment for brain cancer implanted in first human being at CTRC

David Williams is the first human being ever to have a new radiation treatment implanted in the center of his brain tumor. [More]
Tetanus booster shot enhances effect of vaccine therapy for lethal brain tumors

Tetanus booster shot enhances effect of vaccine therapy for lethal brain tumors

An innovative approach using a tetanus booster to prime the immune system enhances the effect of a vaccine therapy for lethal brain tumors, dramatically improving patient survival, according to a study led by Duke Cancer Institute researchers. [More]
Chemotherapy, radiation therapy combination improves outcomes for people with low-grade brain cancer

Chemotherapy, radiation therapy combination improves outcomes for people with low-grade brain cancer

New clinical-trial findings provide further evidence that combining chemotherapy with radiation therapy is the best treatment for people with a low-grade form of brain cancer. The findings come from a phase II study co-led by a researcher at Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and researchers at the University of Maryland and at London Regional Cancer Program in Ontario, Canada. [More]
Pre-clinical data on Novogen’s Cantrixil to be presented at two upcoming conferences

Pre-clinical data on Novogen’s Cantrixil to be presented at two upcoming conferences

Novogen today announces that Professor Gil Mor MD PhD from Yale Medical School will be presenting pre-clinical data on the lead candidate product, Cantrixil, at two upcoming conferences. [More]
Novogen's TRXE-009 therapy shows promise against brain cancer

Novogen's TRXE-009 therapy shows promise against brain cancer

Australian/US biotechnology company, Novogen Limited, today announces that it has confirmed that one of its lead candidate products, TRXE-009, is showing the potential to become an important new therapy in the fight against adult and pediatric brain cancer. [More]
MD Anderson scientists show why some brain cancer patients develop resistance to treatments

MD Anderson scientists show why some brain cancer patients develop resistance to treatments

Scientists at The University of Texas MD Anderson Cancer Center may have discovered why some brain cancer patients develop resistance to standard treatments including radiation and the chemotherapy agent temozolomide. [More]
New cancer drug enters phase I clinical trials in humans

New cancer drug enters phase I clinical trials in humans

A new drug that prompts cancer cells to self-destruct while sparing healthy cells is now entering phase I clinical trials in humans. The drug, called PAC-1, first showed promise in the treatment of pet dogs with spontaneously occurring cancers, and is still in clinical trials in dogs with osteosarcoma. [More]
Researchers one step closer to understanding development of glioblastoma

Researchers one step closer to understanding development of glioblastoma

Glioblastomas are a highly aggressive type of brain tumor, with few effective treatment options. Moffitt Cancer Center researchers are one step closer to understanding glioblastoma development following the identification of a key protein signaling pathway involved in brain tumor stem cell growth and survival. [More]
New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

New TAU study may offer hope to people diagnosed with Glioblastoma multiforme

There are no effective available treatments for sufferers of Glioblastoma multiforme (GBM), the most aggressive and devastating form of brain tumor. The disease, always fatal, has a survival rate of only 6-18 months. [More]
Advertisement
Advertisement